I'll tell you what I think about it and I'm also going to ask Mr. Lévesque to comment and tell us what he would do, as the head of a company, if he had to make decisions about drugs that he was working on.
Market access is a key factor in the innovation chain. When you restrict that access, in Canada, unfortunately it's sure to have a negative impact on the ecosystem.
Here at home, we're already seeing less clinical research being done. Fewer innovative drugs have been launched around the globe and none of those drugs have been launched in Canada. I'm not talking about a company deciding to have its drugs approved in Canada, I'm talking about them deciding to not even launch them in Canada. So patients won't be able to benefit from them.
So there will certainly be repercussions. We're convinced that there will be negative repercussions. We haven't considered that entire chain.
As the CEO of a company working on drugs right now, perhaps Mr. Lévesque could answer this question.